Retinol Supplements Antiviral Action of Interferon in Patients with Chronic Hepatitis C: A Prospective Pilot Study
Sustained virologic response with peg-interferon and ribavirin combination therapy for 48 weeks is still inadequate. Our study examined whether short-term administration of retinol clinically influences the anti-viral activity of interferon early during interferon and ribavirin combination therapy....
Gespeichert in:
| Veröffentlicht in: | Journal of Clinical Biochemistry and Nutrition 2009, Vol.46(1), pp.36-42 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42 |
|---|---|
| container_issue | 1 |
| container_start_page | 36 |
| container_title | Journal of Clinical Biochemistry and Nutrition |
| container_volume | 46 |
| creator | Kohge, Naruaki Sato, Shuichi Hamamoto, Sachiko Akagi, Shuji Uchida, Yasushi Miyake, Tatsuya Mishiro, Tomoko Furuta, Kohichiro Oshima, Naoki Ishine, Junnichi Takahashi, Yoshiko Ishimura, Norihisa Fukuda, Ryo Ishihara, Shunji Amano, Yuji Kinoshita, Yoshikazu |
| description | Sustained virologic response with peg-interferon and ribavirin combination therapy for 48 weeks is still inadequate. Our study examined whether short-term administration of retinol clinically influences the anti-viral activity of interferon early during interferon and ribavirin combination therapy. The control group received 6 MIU of interferon α-2b every day for two weeks and then 3 times a week for 22 weeks intramuscularly plus 600 mg or 800 mg per day of ribavirin orally for 24 weeks. The retinol group, in addition to above treatment, received retinol 30,000 units per day orally for 3 weeks from one week before the start of interferon α-2b plus ribavirin combination therapy. The hepatitis C virus (HCV) RNA negativity rate at 1 week after the end of interferon α-2b and ribavirin combination therapy was 46.7% (28/60) for the retinol group and 31.7% (19/60) for the control group, which was significantly higher for the retinol group. The level of serum HCV RNA in the retinol group was significantly lower at 1 week after beginning treatment as compared to the control group (p |
| doi_str_mv | 10.3164/jcbn.09-48 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2803131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734257568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-63cb3bc2bbf4074a428125788e0bace85121e53cb527c698e4f8558d273a97ed3</originalsourceid><addsrcrecordid>eNpVkV2LEzEUhoO4uLV64w-Q3AnC7OZ7Ml6IpbgfsGBx9Tpk0jPblGlmTDKV_fem27UogYSc8_Ce9_Ai9I6SC06VuNy6NlyQphL6BZpRrUkliVYv0Yw0lFWEkOYcvU5pS4hQUolX6JwRSgRTfIbid8g-DD2-n8axhx2EnPAiZL_30fZ44bIfAh46fBsyxA5i-fmAVzb7J_S3zxu83JSyd_gGxlLPPuHlJ7zAqzikEYrCHvDK90PG93laP75BZ53tE7x9fufo59XXH8ub6u7b9e1ycVc5yUSuFHctbx1r206QWljBNGWy1hpIax1oSRkFWSDJaqcaDaLTUuo1q7ltaljzOfp81B2ndgdrV_yWlcwY_c7GRzNYb_7vBL8xD8PeME04LWeOPjwLxOHXBCmbnU8O-t4GGKZkai6KIal0IT8eSVdWThG60xRKzCEjc8jIkMaIA_z-X18n9G8oBfhyBLYp2wc4ATZm73o4agll6OF60jy13MZGA4H_AVsDptI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734257568</pqid></control><display><type>article</type><title>Retinol Supplements Antiviral Action of Interferon in Patients with Chronic Hepatitis C: A Prospective Pilot Study</title><source>J-STAGE Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Kohge, Naruaki ; Sato, Shuichi ; Hamamoto, Sachiko ; Akagi, Shuji ; Uchida, Yasushi ; Miyake, Tatsuya ; Mishiro, Tomoko ; Furuta, Kohichiro ; Oshima, Naoki ; Ishine, Junnichi ; Takahashi, Yoshiko ; Ishimura, Norihisa ; Fukuda, Ryo ; Ishihara, Shunji ; Amano, Yuji ; Kinoshita, Yoshikazu</creator><creatorcontrib>Kohge, Naruaki ; Sato, Shuichi ; Hamamoto, Sachiko ; Akagi, Shuji ; Uchida, Yasushi ; Miyake, Tatsuya ; Mishiro, Tomoko ; Furuta, Kohichiro ; Oshima, Naoki ; Ishine, Junnichi ; Takahashi, Yoshiko ; Ishimura, Norihisa ; Fukuda, Ryo ; Ishihara, Shunji ; Amano, Yuji ; Kinoshita, Yoshikazu</creatorcontrib><description>Sustained virologic response with peg-interferon and ribavirin combination therapy for 48 weeks is still inadequate. Our study examined whether short-term administration of retinol clinically influences the anti-viral activity of interferon early during interferon and ribavirin combination therapy. The control group received 6 MIU of interferon α-2b every day for two weeks and then 3 times a week for 22 weeks intramuscularly plus 600 mg or 800 mg per day of ribavirin orally for 24 weeks. The retinol group, in addition to above treatment, received retinol 30,000 units per day orally for 3 weeks from one week before the start of interferon α-2b plus ribavirin combination therapy. The hepatitis C virus (HCV) RNA negativity rate at 1 week after the end of interferon α-2b and ribavirin combination therapy was 46.7% (28/60) for the retinol group and 31.7% (19/60) for the control group, which was significantly higher for the retinol group. The level of serum HCV RNA in the retinol group was significantly lower at 1 week after beginning treatment as compared to the control group (p<0.01). Furthermore, serum 2,5'AS protein at 1 week after beginning treatment was significantly higher in the retinol group (p = 0.0002). The results suggest that retinol supplement increases the antiviral effect of interferon α-2b plus ribavirin only during the administration of IFN α-2b, ribavirin and retinol in patients with chronic hepatitis C.</description><identifier>ISSN: 0912-0009</identifier><identifier>EISSN: 1880-5086</identifier><identifier>DOI: 10.3164/jcbn.09-48</identifier><identifier>PMID: 20104263</identifier><language>eng</language><publisher>Japan: SOCIETY FOR FREE RADICAL RESEARCH JAPAN</publisher><subject>chronic hepatitis ; hepatitis C ; Original ; retinol ; ribavirin ; virological response</subject><ispartof>Journal of Clinical Biochemistry and Nutrition, 2009, Vol.46(1), pp.36-42</ispartof><rights>2009 by The Editorial Secretariat of JCBN</rights><rights>Copyright © 2010 JCBN 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-63cb3bc2bbf4074a428125788e0bace85121e53cb527c698e4f8558d273a97ed3</citedby><cites>FETCH-LOGICAL-c524t-63cb3bc2bbf4074a428125788e0bace85121e53cb527c698e4f8558d273a97ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803131/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803131/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20104263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kohge, Naruaki</creatorcontrib><creatorcontrib>Sato, Shuichi</creatorcontrib><creatorcontrib>Hamamoto, Sachiko</creatorcontrib><creatorcontrib>Akagi, Shuji</creatorcontrib><creatorcontrib>Uchida, Yasushi</creatorcontrib><creatorcontrib>Miyake, Tatsuya</creatorcontrib><creatorcontrib>Mishiro, Tomoko</creatorcontrib><creatorcontrib>Furuta, Kohichiro</creatorcontrib><creatorcontrib>Oshima, Naoki</creatorcontrib><creatorcontrib>Ishine, Junnichi</creatorcontrib><creatorcontrib>Takahashi, Yoshiko</creatorcontrib><creatorcontrib>Ishimura, Norihisa</creatorcontrib><creatorcontrib>Fukuda, Ryo</creatorcontrib><creatorcontrib>Ishihara, Shunji</creatorcontrib><creatorcontrib>Amano, Yuji</creatorcontrib><creatorcontrib>Kinoshita, Yoshikazu</creatorcontrib><title>Retinol Supplements Antiviral Action of Interferon in Patients with Chronic Hepatitis C: A Prospective Pilot Study</title><title>Journal of Clinical Biochemistry and Nutrition</title><addtitle>J. Clin. Biochem. Nutr.</addtitle><description>Sustained virologic response with peg-interferon and ribavirin combination therapy for 48 weeks is still inadequate. Our study examined whether short-term administration of retinol clinically influences the anti-viral activity of interferon early during interferon and ribavirin combination therapy. The control group received 6 MIU of interferon α-2b every day for two weeks and then 3 times a week for 22 weeks intramuscularly plus 600 mg or 800 mg per day of ribavirin orally for 24 weeks. The retinol group, in addition to above treatment, received retinol 30,000 units per day orally for 3 weeks from one week before the start of interferon α-2b plus ribavirin combination therapy. The hepatitis C virus (HCV) RNA negativity rate at 1 week after the end of interferon α-2b and ribavirin combination therapy was 46.7% (28/60) for the retinol group and 31.7% (19/60) for the control group, which was significantly higher for the retinol group. The level of serum HCV RNA in the retinol group was significantly lower at 1 week after beginning treatment as compared to the control group (p<0.01). Furthermore, serum 2,5'AS protein at 1 week after beginning treatment was significantly higher in the retinol group (p = 0.0002). The results suggest that retinol supplement increases the antiviral effect of interferon α-2b plus ribavirin only during the administration of IFN α-2b, ribavirin and retinol in patients with chronic hepatitis C.</description><subject>chronic hepatitis</subject><subject>hepatitis C</subject><subject>Original</subject><subject>retinol</subject><subject>ribavirin</subject><subject>virological response</subject><issn>0912-0009</issn><issn>1880-5086</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpVkV2LEzEUhoO4uLV64w-Q3AnC7OZ7Ml6IpbgfsGBx9Tpk0jPblGlmTDKV_fem27UogYSc8_Ce9_Ai9I6SC06VuNy6NlyQphL6BZpRrUkliVYv0Yw0lFWEkOYcvU5pS4hQUolX6JwRSgRTfIbid8g-DD2-n8axhx2EnPAiZL_30fZ44bIfAh46fBsyxA5i-fmAVzb7J_S3zxu83JSyd_gGxlLPPuHlJ7zAqzikEYrCHvDK90PG93laP75BZ53tE7x9fufo59XXH8ub6u7b9e1ycVc5yUSuFHctbx1r206QWljBNGWy1hpIax1oSRkFWSDJaqcaDaLTUuo1q7ltaljzOfp81B2ndgdrV_yWlcwY_c7GRzNYb_7vBL8xD8PeME04LWeOPjwLxOHXBCmbnU8O-t4GGKZkai6KIal0IT8eSVdWThG60xRKzCEjc8jIkMaIA_z-X18n9G8oBfhyBLYp2wc4ATZm73o4agll6OF60jy13MZGA4H_AVsDptI</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Kohge, Naruaki</creator><creator>Sato, Shuichi</creator><creator>Hamamoto, Sachiko</creator><creator>Akagi, Shuji</creator><creator>Uchida, Yasushi</creator><creator>Miyake, Tatsuya</creator><creator>Mishiro, Tomoko</creator><creator>Furuta, Kohichiro</creator><creator>Oshima, Naoki</creator><creator>Ishine, Junnichi</creator><creator>Takahashi, Yoshiko</creator><creator>Ishimura, Norihisa</creator><creator>Fukuda, Ryo</creator><creator>Ishihara, Shunji</creator><creator>Amano, Yuji</creator><creator>Kinoshita, Yoshikazu</creator><general>SOCIETY FOR FREE RADICAL RESEARCH JAPAN</general><general>the Society for Free Radical Research Japan</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100101</creationdate><title>Retinol Supplements Antiviral Action of Interferon in Patients with Chronic Hepatitis C: A Prospective Pilot Study</title><author>Kohge, Naruaki ; Sato, Shuichi ; Hamamoto, Sachiko ; Akagi, Shuji ; Uchida, Yasushi ; Miyake, Tatsuya ; Mishiro, Tomoko ; Furuta, Kohichiro ; Oshima, Naoki ; Ishine, Junnichi ; Takahashi, Yoshiko ; Ishimura, Norihisa ; Fukuda, Ryo ; Ishihara, Shunji ; Amano, Yuji ; Kinoshita, Yoshikazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-63cb3bc2bbf4074a428125788e0bace85121e53cb527c698e4f8558d273a97ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>chronic hepatitis</topic><topic>hepatitis C</topic><topic>Original</topic><topic>retinol</topic><topic>ribavirin</topic><topic>virological response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kohge, Naruaki</creatorcontrib><creatorcontrib>Sato, Shuichi</creatorcontrib><creatorcontrib>Hamamoto, Sachiko</creatorcontrib><creatorcontrib>Akagi, Shuji</creatorcontrib><creatorcontrib>Uchida, Yasushi</creatorcontrib><creatorcontrib>Miyake, Tatsuya</creatorcontrib><creatorcontrib>Mishiro, Tomoko</creatorcontrib><creatorcontrib>Furuta, Kohichiro</creatorcontrib><creatorcontrib>Oshima, Naoki</creatorcontrib><creatorcontrib>Ishine, Junnichi</creatorcontrib><creatorcontrib>Takahashi, Yoshiko</creatorcontrib><creatorcontrib>Ishimura, Norihisa</creatorcontrib><creatorcontrib>Fukuda, Ryo</creatorcontrib><creatorcontrib>Ishihara, Shunji</creatorcontrib><creatorcontrib>Amano, Yuji</creatorcontrib><creatorcontrib>Kinoshita, Yoshikazu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Clinical Biochemistry and Nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kohge, Naruaki</au><au>Sato, Shuichi</au><au>Hamamoto, Sachiko</au><au>Akagi, Shuji</au><au>Uchida, Yasushi</au><au>Miyake, Tatsuya</au><au>Mishiro, Tomoko</au><au>Furuta, Kohichiro</au><au>Oshima, Naoki</au><au>Ishine, Junnichi</au><au>Takahashi, Yoshiko</au><au>Ishimura, Norihisa</au><au>Fukuda, Ryo</au><au>Ishihara, Shunji</au><au>Amano, Yuji</au><au>Kinoshita, Yoshikazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retinol Supplements Antiviral Action of Interferon in Patients with Chronic Hepatitis C: A Prospective Pilot Study</atitle><jtitle>Journal of Clinical Biochemistry and Nutrition</jtitle><addtitle>J. Clin. Biochem. Nutr.</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>46</volume><issue>1</issue><spage>36</spage><epage>42</epage><pages>36-42</pages><issn>0912-0009</issn><eissn>1880-5086</eissn><abstract>Sustained virologic response with peg-interferon and ribavirin combination therapy for 48 weeks is still inadequate. Our study examined whether short-term administration of retinol clinically influences the anti-viral activity of interferon early during interferon and ribavirin combination therapy. The control group received 6 MIU of interferon α-2b every day for two weeks and then 3 times a week for 22 weeks intramuscularly plus 600 mg or 800 mg per day of ribavirin orally for 24 weeks. The retinol group, in addition to above treatment, received retinol 30,000 units per day orally for 3 weeks from one week before the start of interferon α-2b plus ribavirin combination therapy. The hepatitis C virus (HCV) RNA negativity rate at 1 week after the end of interferon α-2b and ribavirin combination therapy was 46.7% (28/60) for the retinol group and 31.7% (19/60) for the control group, which was significantly higher for the retinol group. The level of serum HCV RNA in the retinol group was significantly lower at 1 week after beginning treatment as compared to the control group (p<0.01). Furthermore, serum 2,5'AS protein at 1 week after beginning treatment was significantly higher in the retinol group (p = 0.0002). The results suggest that retinol supplement increases the antiviral effect of interferon α-2b plus ribavirin only during the administration of IFN α-2b, ribavirin and retinol in patients with chronic hepatitis C.</abstract><cop>Japan</cop><pub>SOCIETY FOR FREE RADICAL RESEARCH JAPAN</pub><pmid>20104263</pmid><doi>10.3164/jcbn.09-48</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0912-0009 |
| ispartof | Journal of Clinical Biochemistry and Nutrition, 2009, Vol.46(1), pp.36-42 |
| issn | 0912-0009 1880-5086 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2803131 |
| source | J-STAGE Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | chronic hepatitis hepatitis C Original retinol ribavirin virological response |
| title | Retinol Supplements Antiviral Action of Interferon in Patients with Chronic Hepatitis C: A Prospective Pilot Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A16%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retinol%20Supplements%20Antiviral%20Action%20of%20Interferon%20in%20Patients%20with%20Chronic%20Hepatitis%20C:%20A%20Prospective%20Pilot%20Study&rft.jtitle=Journal%20of%20Clinical%20Biochemistry%20and%20Nutrition&rft.au=Kohge,%20Naruaki&rft.date=2010-01-01&rft.volume=46&rft.issue=1&rft.spage=36&rft.epage=42&rft.pages=36-42&rft.issn=0912-0009&rft.eissn=1880-5086&rft_id=info:doi/10.3164/jcbn.09-48&rft_dat=%3Cproquest_pubme%3E734257568%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734257568&rft_id=info:pmid/20104263&rfr_iscdi=true |